ZOMETA International Site for Healthcare Professionals Outside of the US
ZOMETA in Multiple Myeloma
This is an international site for Zometa® (zoledronic acid) and is intended for Health Care Professionals outside the U.S. The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country.
|
Print|
Text size:
ZOMETA is indicated for the prevention of SREs in patients with advanced malignancies involving bone.1
*SRE=skeletal-related event—defined as pathological fracture, spinal cord compression, radiation or surgery to bone, or tumour-induced hypercalcaemia.1
Disclaimer: This is an international website for ZOMETA® (zoledronic acid) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.
About Novartis Oncology | Site Guide | Contact Us
Use of this website is subject to our Terms of Use and Privacy Statement
© Novartis AG.
Italiano
Français
Español
Deutsch
English
